GO
| HSI1 | 26,572.46 | -500.57 | 232.79B |
| HSCEI1 | 9,397.96 | -201.10 | 90.03B |
| Back Zoom + Zoom - Block Traded | |
|
2025-11-14 14:04:31 JD HEALTH (06618.HK) management, confident in achieving or even surpassing its 2025 annual revenue growth target of 22%, has raised its adjusted net profit target to RMB6.2 billion from around RMB5.6-5.7 billion, according to a report from Morgan Stanley. JD HEALTH's 3Q25 revenue increased by 28.7% YoY to RMB17.1 billion, 4% higher than market expectations, which Morgan Stanley attributed to strong first-party sales (primarily pharmaceuticals) and advertising revenue (mainly from nutritional and health products). Morgan Stanley gave JD HEALTH an Equalweight rating and a target price of HKD60. ~ AAStocks Financial News Web Site: www.aastocks.com | |